Research summary
Research HubThymosin Alpha-1
Clinical — 10 studies
Thymosin Alpha-1 is a naturally occurring thymic peptide studied extensively for its role in immune system regulation, host defense signaling, and immune cell maturation.
Being studied for
- Innate and adaptive immune modulation
- T-cell maturation and signaling
- Host defense research
Published Research
Evidence profile
Controlled human evidence
10 cited publications · 1 primary trial
Findings below belong to the studies that reported them. They describe the material and conditions those authors used, not this product, and not an outcome to expect.
Supporting evidence
Treatment with thymosin alpha-1 increases fertilizing capacity of sperm of infertile men: a multicenter trial
Naz RK et al. · Archives of andrology · 1995
The study reportedIt would appear that T alpha 1 may have clinical application in the diagnosis and treatment of male infertility especially mediated through defective sperm function.
Thymosin alpha 1 alleviates inflammation and prevents infection in patients with severe acute pancreatitis through immune regulation: a systematic review and meta-analysis
Tian Y et al. · Frontiers in immunology · 2025
The study reportedTα1 can regulate the balance of immune cells and alleviate immune suppression in SAP patients, including increasing CD4+ T cells and CD4+/CD8+ ratios. Tα1 may exert anti-inflammatory and extrapancreatic infection-preventive effects on SAP patients and improve their condition or prognosis.
Thymosin Alpha 1 Plus Routine Treatment for the Acute Exacerbation of Chronic Obstructive Pulmonary Disease: A Systematic Review and Meta-Analysis
Cao A et al. · Journal of the College of Physicians and Surgeons--Pakistan : JCPSP · 2024
The study reportedMore high-quality randomised controlled trials are needed to further confirm Thymosin alpha 1 efficacy. Key Words: Thymosin alpha 1, Efficacy, Acute exacerbation of chronic obstructive pulmonary disease, Meta-analysis.
Comprehensive Review of the Safety and Efficacy of Thymosin Alpha 1 in Human Clinical Trials
Dinetz E et al. · Alternative therapies in health and medicine · 2024
The study reportedBased on substantial evidence from clinical trials, Tα1 emerges as a well-tolerated and effective immune modulator. The FDA›s restriction appears unfounded, as Tα1 has shown safety and efficacy beyond the initially specified conditions.
The efficacy of thymosin alpha-1 therapy in moderate to critical COVID-19 patients: a systematic review, meta-analysis, and meta-regression
Soeroto AY et al. · Inflammopharmacology · 2023
The study reportedOur study suggests that treatment with thymosin alpha-1 may reduce mortality rate in moderate to critical COVID-19 patients. Randomized clinical trials (RCTs) are still required to verify the findings of our study.
Additional indexed literature (5)
- Clinical · Mechanistic studyA Pilot Trial of Thymalfasin (Thymosin-α-1) to Treat Hospitalized Patients With Hypoxemia and Lymphocytopenia Due to Coronavirus Disease 2019 Infection
Shehadeh F et al. · The Journal of infectious diseases · 2023 · PMID 36056913
- Clinical · Mechanistic studyThymosin alpha 1 restores the immune homeostasis in lymphocytes during Post-Acute sequelae of SARS-CoV-2 infection
Minutolo A et al. · International immunopharmacology · 2023 · PMID 36989892
- Clinical · Mechanistic study[Thymosin alpha 1 for the adjuvant treatment of coronavirus disease 2019: a retrospective cohort study]
Wang T et al. · Zhonghua wei zhong bing ji jiu yi xue · 2022 · PMID 35728851
- Clinical · Mechanistic studyEfficacy of Thymosin Alpha 1 in the Treatment of COVID-19: A Multicenter Cohort Study
Liu J et al. · Frontiers in immunology · 2021 · PMID 34408744
- Preclinical · Mechanistic studyThymosin α1 reverses oncolytic adenovirus-induced M2 polarization of macrophages to improve antitumor immunity and therapeutic efficacy
Liu K et al. · Cell reports. Medicine · 2024 · PMID 39357524
Published studies summarised here concern the specific investigational or pharmaceutical materials and study conditions described by their authors. Their findings are not performance claims for Cobalt Peptides material. Citations verified against PubMed on 2026-08-09.
Thymosin Alpha-1 is approved in some regions for specific indications and is presented here solely in the context of published scientific research.
Notice
All information on this page is provided strictly for laboratory research and educational purposes only.